Bibliographic citations
Veira, R., (2024). Evaluación de la eficacia de la eritropoyetina en el tratamiento de la anemia en pacientes con enfermedad renal crónica sometidos a hemodiálisis [Universidad Nacional San Luis Gonzaga]. https://hdl.handle.net/20.500.13028/5831
Veira, R., Evaluación de la eficacia de la eritropoyetina en el tratamiento de la anemia en pacientes con enfermedad renal crónica sometidos a hemodiálisis []. PE: Universidad Nacional San Luis Gonzaga; 2024. https://hdl.handle.net/20.500.13028/5831
@misc{renati/2015377,
title = "Evaluación de la eficacia de la eritropoyetina en el tratamiento de la anemia en pacientes con enfermedad renal crónica sometidos a hemodiálisis",
author = "Veira Reynoso, Romina Rossiel",
publisher = "Universidad Nacional San Luis Gonzaga",
year = "2024"
}
To analyze the efficacy of erythropoietin in the treatment of anemia in patients with chronic kidney disease undergoing hemodialysis. Methodological Strategy: Quantitative study, non-experimental, descriptive design. Medical records and complementary documents of patients receiving care at a private dialysis clinic were analyzed. The technique used was documentary analysis. The medical records and complementary documents of 52 adult patients who received care at the private dialysis clinic were included, determined by systematic probabilistic sampling. Results and Conclusions: The average age of the hemodialysis patients was 59.36 years, the median age was 62.5 years, and the mode was 65 years. The age range was 46 years, with the youngest participant being 37 years old and the oldest 83 years old. According to hemoglobin levels, 19.2% had 10 g/dL or less (8.1% - 10.0 g/dL) in the pre-EPO stage, and 80.8% had more than 10 g/dL (10.3% - 11.2 g/dL). In the post-EPO stage, 13.5% had values of 10 g/dL or less (9.0% - 9.6 g/dL), and 86.5% had more than 10 g/dL (11.0% - 12.5 g/dL). According to serum iron levels, 86.5% had 100 mcg/dL or less (46.97 – 98.4 mcg/dL) in the pre-EPO stage, and 13.5% had more than 100 mg/dL (110 – 120.6 mcg/dL). In the post-EPO stage, 80.8% had values of 100 mcg/dL or less (55 - 92 mcg/dL), and 19.2% had more than 100 mg/dL (104 – 200 mcg/dL).
This item is licensed under a Creative Commons License